REMINDER: Our user survey closes on Friday, please submit your responses here.
In fact, looking back at my post on April 29th (I'll repost in a minute) it included 2 of the companies I mentioned being in the same stage (MTPH & HEMO). Could have save SP Angels a bit of time if I'd just given my notes to them. My calculations made out that the N4P's market cap should be around £27m, which would equate to a SP of around 15p, while we are waiting on securing an agreement.
I'm glad they added some peer analysis (page 5). I wrote a while back where I thought N4P sat with the other pharmas and does highlight that the market cap should be much higher at this current stage.
Then again, the companies it does make comparisons with probably don't leave their shareholders waiting ages for news.
Take note Nigel...
I don't think that Nigel needs to wait for the American patent to be approved Dan.
Most pharma companies are global, certainly one of the MTAs is, so to wait for a patent approval in one region doesn't make sense.
Also, once a patent is applied for, you have protection over your product already while waiting for the approval.
Looks like the SP has retraced a bit since the end of last week. Doesn't really concern me as it's not based on news so it'll be a bit liquid until some arrives.
Also appears that some messages this morning disappeared which is a bit bizarre as I don't think there was anything too bad in them, just some voicing their view. Not a big fan of censorship as it's always good to have a balanced view.
Anyway, cracking open a bottle of wine for an early start to the weekend, who can resist with the weather lately!
A lot of us are sat, quite heavily, in good positions waiting an update but it's not healthy to sit worrying about the SP every hour.
Get some sunshine!
DYOR
Personally I think Nigel would be mad to accept an offer for the company at this stage and the way forward is through licencing. If you think of the potential of the company, one collaboration could bring in anything from 25 - 50 million dependant on the market for what it's being used for. If it's for covid, then that is an absolutely huge market (7 billion people needing a good product. Just capturing 10% of that market is 700 million people).
Once N4P is in a position to be bringing in money through 1 or more collaborations then the market cap is determined differently. Currently it's based on the value of the asset, Nuvec. When generating annual profit, standard practise, but not always, is to calculate the annual earnings and multiply the value by 10 to get a company's market cap.
I would be looking for a much higher SP in the future should the collaborations work out and we start licensing agreements.
Anyway, DYOR
https://edition.cnn.com/2021/06/01/health/mrna-vaccines-covid-future/index.html
Not heard back from them bidnolid but I expect after the ************* interview they'll want to focus on current day to day running. I'm hoping Nigel is running out of ink signing up more MTAs.
I would be very interested to know how these collaborations came about, that's what I would have been asking Nigel. Did N4P approach these companies and say look at Nuvec or is it that Nuvec is starting to make a lot of noise in the pharma community which is bringing about all these collaborations to want to talk to N4P?
Certainly has been a number of big buys coming in this week so looks like the company is gaining more attention!
When I was doing my own research, there was a company I noticed quite similar to N4P going down the oral covid vaccine route. They have there own platform called bacTRL, which interesting enough they are now in trials in OZ with an upgraded version called bacTRL-Spike.
You can see the potential they have if you watch this video (skip to 15:10)
https://www.youtube.com/watch?v=0rSIZSlcRXA&t=896s
Possible that N4P could be in a similar position in the future...
Just gone in for a top up while there's a bit of hesitancy in the SP increasing further. I think that'll be my last one now, but with such a good update I feel we're being de-risked each week now. @************ will probably claim it as theirs :).
Came through as a sell as per usual...
DYOR
Lovely update by Nigel this morning for those amongst us who have been getting a bit edgy waiting on news. Looks like we're in for a good summer, even if the weather has been terrible the last few weeks.
Not too worried about the small increase for now, as I expect it'll start to build towards a new level as we begin to enter the next phase for the company.
I prefer this site, it's the public portal.
https://portal.uspto.gov/pair/PublicPair
You can see the full transaction history if you put the US publication no. (20200392005) :)